Morning Wire Pill Politics: The Supreme Battle Over Mifepristone | Saturday Extra
Mar 23, 2024
Erin Hawley, a senior counsel at Alliance Defending Freedom and lead attorney in the pivotal Supreme Court case on mifepristone, dives into the contentious issues surrounding this abortion drug. She discusses the rise in medication abortions and the critical role of initial doctor visits in ensuring safety. Hawley highlights the alarming health risks of mifepristone, including severe complications and regulatory changes during the pandemic. Legal arguments surrounding the FDA's oversight and patient safety concerns add further depth to this critical societal debate.
AI Snips
Chapters
Transcript
Episode notes
Supreme Court Case
- The Supreme Court will hear arguments on restricting access to mifepristone, an abortion drug.
- Erin Hawley, who helped overturn Roe v. Wade, leads this case.
Reckless Removal
- The FDA's removal of safety measures for mifepristone is concerning.
- Women can now take this drug without a healthcare provider's supervision.
Three-Visit Protocol
- Originally, three doctor visits were required for mifepristone: initial assessment, administering the second drug, and follow-up.
- These visits allowed for checking for ectopic pregnancies, assessing gestational age, explaining expectations, and identifying complications.